Market capitalization | $0.00 |
EBIT (operating result TTM) EBIT | $-32.65m |
Short interest | 3.70% |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
1 Analyst has issued a forecast OncoSec Medical Incorporated:
1 Analyst has issued a forecast OncoSec Medical Incorporated:
Jul '22 |
+/-
%
|
||
Net Profit | -34 -34 |
24%
24%
|
|
Depreciation and Amortization | 1.07 1.07 |
1%
1%
|
|
Stock Compensation | 1.65 1.65 |
-
|
|
Operating Cash Flow | -32 -32 |
22%
22%
|
|
Investments | 0.24 0.24 |
70%
70%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -32 -32 |
22%
22%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
OncoSec Medical, Inc. is a biotechnology company, which engages in designing, developing, and commercializing therapies for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered inPennington, NJ.
Head office | United States |
CEO | Robert Arch |
Employees | 41 |
Founded | 2008 |
Website | www.oncosec.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.